Sexual Dysfunction

Effect of Testosterone Replacement Treatment in Testosterone Deficiency Syndrome Patients with Metabolic Syndrome

Seung Min Jeong, Byeong Kuk Ham, Min Gu Park1, Mi Mi Oh, Duck Ki Yoon, Je Jong Kim, Du Geon Moon

Department of Urology, Korea University College of Medicine, College of Medicine, Inje University

Purpose: This study was conducted to investigate the effect of testosterone replacement treatment (TRT) in testosterone deficiency syndrome (TDS) patients with metabolic syndrome.

Materials and Methods: We reviewed the data of 200 men who were diagnosed with TDS and were undergoing TRT between August 2006 and August 2009. The 200 patients were divided into two groups (group 1: 71 patients with metabolic syndrome, group 2: 129 patients without metabolic syndrome) depending on metabolic syndrome, which was diagnosed according to the NCEP III criteria for Asians. Age, BMI (body mass index), waist circumference, serologic tests, AMS (the Aging Males' Symptoms scale), and IIEF (International Index of Erectile Function) were measured.

Results: In group 1, waist circumference and fasting glucose were significantly decreased; hemoglobin and total testosterone were increased; and the somatovegetative scale score of the AMS, the total AMS score, the erectile function score of the IIEF, the overall satisfaction score of the IIEF, and the total IIEF score were significantly improved after TRT. On the other hand, in group 2, waist circumference, BMI, total cholesterol, LDL, and fasting glucose were significantly decreased; hemoglobin and total testosterone were increased; and the 2 subscale scores of the AMS (psychologic and somatovegetative), the total AMS score, all subscale scores of the IIEF, and the total IIEF score were significantly improved after TRT.

Conclusions: Overall, the patients who had TDS with metabolic syndrome showed less improvement in AMS, IIEF, and serum variables. Therefore, the correction of metabolic syndrome, such as diabetes, obesity, and hypertension, should be considered during TRT.

Key Words: Hormone replacement therapy; Metabolic syndrome X; Testosterone

INTRODUCTION

Recently in Korea, the prevalence rates of cardiovascular diseases, diabetes mellitus, and obesity, which are thought to suggest metabolic syndrome, are increasing, and mortality statistics show that cerebrovascular diseases, cardiac disease, and diabetes mellitus are ranked numbers 2, 3, and 5, respectively, in males [1]. Accordingly, there have been many investigations of the correlation between cardiovascular disease and metabolic syndrome.

In 1988, Reaven suggested the basic characteristics of metabolic syndrome as the group of insulin resistance risk factors, such as hyperinsulinemia, glucose intolerance, dyslipidemia, and hypertension [2]. Afterwards, various research allowed the World Health Organization (WHO) to define the term metabolic syndrome for the first time in 1998 [3]. Since then, on the basis of basic factors such as diabetes mellitus, obesity, dyslipidemia, hypertension, and albuminuria, the National Cholesterol Education Program (NCEP) Adult Treatment Panel III, the European
Group for the Study of Insulin Resistance (EGIR), and others have suggested diagnostic criteria for metabolic syndrome [4,5].

In many recent epidemiologic investigations, it has been revealed that there is a close relationship between obesity and low serum testosterone values, and metabolic syndrome and type 2 diabetes mellitus are also known to be related to low serum testosterone levels [6]. Also, it has been reported that low serum testosterone levels can be a risk factor for diabetes mellitus and metabolic syndrome [6].

Whereas many researchers have reported on the correlation between metabolic syndrome and testosterone, none have reported on the effectiveness of testosterone replacement therapy (TRT) in patients with testosterone deficiency syndrome (TDS) accompanied by metabolic syndrome. Thus, in the present study, we tried to determine the effect of TRT in TDS patients with metabolic syndrome.

MATERIALS AND METHODS

1. Subjects
Among TDS patients (testosterone < 3.5 ng/dl) who visited the urology clinic at this hospital from August 2007 to August 2010, 200 males who received TRT for 30 weeks or more were investigated retrospectively.

A total of 71 subjects were assigned to the patient group that met the diagnostic criteria of metabolic syndrome (group 1) and 129 subjects to the patient group that did not meet the diagnostic criteria of metabolic syndrome (group 2).

**TABLE 1. Comparisons of BMI, Hb, PSA, glucose, lipid profile, and total testosterone between group I and group II before TRT (independent t-test)**

|                        | Group 1        | Group 2        | p-value |
|------------------------|----------------|----------------|---------|
| Age (yr)               | 57.8±9.9       | 57.6±9.8       | 0.869   |
| BMI (kg/m²)            | 26.35±2.47     | 24.56±2.39     | <0.001* |
| Waist (inch)           | 35.86±1.50     | 33.81±2.06     | <0.001* |
| Hb (mg/dl)             | 14.61±1.42     | 14.73±1.19     | 0.541   |
| PSA (ng/dl)            | 1.02±0.79      | 1.52±2.57      | 0.067   |
| Glucose (mg/dl)        | 121.1±32.1     | 111.5±30.1     | <0.001* |
| Total cholesterol (mg/dl) | 186.38±39.90 | 182.93±37.82 | 0.573   |
| Triglyceride (mg/dl)   | 192.69±180.80  | 206.80±213.91  | 0.677   |
| LDL cholesterol (mg/dl)| 113.41±38.90  | 109.17±29.86   | 0.485   |
| HDL cholesterol (mg/dl)| 42.15±9.57    | 47.72±21.11    | 0.004*  |
| Total testosterone     | 2.31±0.82      | 2.52±1.12      | 0.164   |

Group 1: TDS patients with metabolic syndrome, Group 2: TDS patients without metabolic syndrome, BMI: body mass index, PSA: prostate-specific antigen, LDL: low-density lipoprotein, HDL: high-density lipoprotein. *: statistical significance, p<0.05 in independent t-test between group 1 and group 2

2. Methods
Testosterone undecanoate 1 g was used for TRT and was injected intramuscularly at an interval of 10 to 14 weeks.

The criteria for metabolic syndrome were based on the NCEP III criteria for Asians. Among the five standards of systolic blood pressure ≥ 130 or diastolic blood pressure ≥ 85 mmHg or taking hypertension medication, fasting blood glucose (FBG) ≥ 110 mg/dl or taking hypoglycemic medication, fasting triglyceride ≥ 150 mg/dl, fasting HDL cholesterol ≤ 40 mg/dl, and waist circumference ≥ 90 cm (35.4 inches), those patients who met three or more criteria were determined to have metabolic syndrome. The evaluation of erectile dysfunction used the International Index of Erectile Function (IIEF) survey, and the evaluation of TDS symptoms used the AMS (Aging Males’ Symptoms) survey.

Blood pressure maintained at a stable state for 10 minutes or more was measured by a single investigator with a mercury hemomanometer at the right upper arm, and waist circumference was measured with a tape measure at the thinnest part in the middle between below the ribs and the iliac crest while the patient had his or her breath comfortably released. Serum tests involved taking blood between 0800 and 1100 after 8 hours or more of fasting, and hemoglobin, prostate-specific antigen (PSA), glucose, triglyceride, total cholesterol, HDL cholesterol, LDL cholesterol, and serum testosterone were measured.

3. Statistical analysis
Using independent T-tests and paired T-tests, differences between the two groups and the differences between before and after treatment of each group were compared and analyzed. All statistical analysis used the statistical software SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA), and p<0.05 was considered to be statistically significant.

**TABLE 2. Comparisons of IIEF and AMS scores between group 1 and group 2 before TRT (independent t-test)**

|                        | Group 1        | Group 2        | p-value |
|------------------------|----------------|----------------|---------|
| IIEF (erectile function)| 15.03±8.72     | 14.96±8.59     | 0.970   |
| IIEF (orgasm)           | 5.07±3.43      | 5.30±3.69      | 0.751   |
| IIEF (sexual desire)    | 5.79±2.40      | 5.68±2.39      | 0.815   |
| IIEF (sexual satisfaction)| 5.87±4.12     | 6.15±4.08      | 0.736   |
| IIEF (overall satisfaction)| 5.31±2.98     | 5.37±2.65      | 0.912   |
| IIEF (total)            | 37.08±18.49    | 37.46±18.32    | 0.916   |
| AMS (psychologic)       | 10.19±17.09    | 7.13±4.82      | 0.885   |
| AMS (somatovegetative)  | 18.92±16.53    | 14.10±6.20     | 0.030*  |
| AMS (sexual)            | 14.50±16.94    | 11.60±6.51     | 0.118   |
| AMS (total)             | 37.23±20.21    | 32.89±15.01    | 0.116   |

Group 1: TDS patients with metabolic syndrome, Group 2: TDS patients without metabolic syndrome, IIEF: International Index of Erectile Function, AMS: The Aging Males’ Symptoms scale, *: statistical significance, p<0.05 in independent t-test between group 1 and group 2
## RESULTS

1. Differences between TDS patients with and without metabolic syndrome before TRT

In the pretreatment comparison of the patient group with metabolic syndrome (group 1) and the patient group without metabolic syndrome (group 2), BMI, waist circumference, FBG, and HDL cholesterol showed statistically significant differences. In the survey results, the pretreatment somatovegetative subscale of the AMS showed a significant difference (Table 1, 2).

2. Effect of TRT in TDS patients with metabolic syndrome (group 1)

In group 1, after TRT, there was a statistically significant reduction in waist circumference, an increase in serum hemoglobin and testosterone, and a reduction in FBG. In the survey results, 2 detailed items (erectile function, overall satisfaction) and the overall score of the IIEF and 1 detailed item (somatovegetative subscale) and the overall score of the AMS showed statistically significant increases (Table 3, 4).

### TABLE 3. Comparisons of BMI, waist circumference, Hb, PSA, lipid profile, and total testosterone between before and after TRT in groups 1 and 2 (paired t-test)

|                | Group 1 | Group 2 | p-value | p-value |
|----------------|---------|---------|---------|---------|
| BMI (kg/m²)    | 26.35±2.47 | 26.19±2.63 | 0.174   | 24.56±2.39 | 24.26±2.44 | <0.001* |
| Waist (inch)   | 35.86±1.50 | 35.56±1.76 | 0.008* | 33.81±2.06 | 33.67±1.94 | 0.046* |
| Hb (mg/dl)     | 14.61±1.42 | 15.54±1.51 | <0.001* | 14.73±1.19 | 15.29±1.38 | <0.001* |
| PSA (ng/dl)    | 1.00±0.77  | 1.17±1.01  | 0.061   | 1.44±2.77  | 1.32±1.27  | 0.627   |
| Glucose (mg/dl)| 121.1±32.1 | 116.6±28.1 | 0.016* | 115.5±30.1 | 107.3±26.1 | 0.045* |
| Total cholesterol (mg/dl) | 187.30±49.52 | 184.06±39.94 | 0.602 | 183.37±38.06 | 165.65±32.03 | <0.001* |
| Triglyceride (mg/dl) | 196.55±203.69 | 160.85±75.73 | 0.193 | 186.39±172.13 | 150.15±93.11 | 0.094 |
| LDL (mg/dl)    | 113.42±35.82 | 110.50±34.74 | 0.633 | 105.59±28.65 | 97.92±32.66 | 0.034* |
| HDL (mg/dl)    | 42.09±10.11 | 43.02±11.61 | 0.479   | 46.82±12.91 | 44.67±11.83 | 0.094   |
| Total testosterone (ng/ml) | 23.18±2.82   | 24.17±2.62 | <0.001* | 25.22±1.12 | 4.12±1.92 | <0.001* |

Group 1: TDS patients with metabolic syndrome, Group 2: TDS patients without metabolic syndrome, BMI: body mass index, PSA: prostate-specific antigen, LDL: low-density lipoprotein, HDL high-density lipoprotein. *: statistical significance, p<0.05 in paired t-test between before and after TRT

### TABLE 4. Comparisons of IIEF and AMS scores between before and after TRT in groups 1 and 2 (paired t-test)

|                | Group 1 | Group 2 | p-value | p-value |
|----------------|---------|---------|---------|---------|
| IIEF (erectile function) | 10.95±7.81 | 15.40±3.32 | 0.045* | 11.98±6.96 | 18.35±6.81 | <0.001* |
| IIEF (orgasm)     | 4.15±3.56  | 5.70±3.33  | 0.057   | 4.32±3.41  | 6.47±2.76  | <0.001* |
| IIEF (sexual desire) | 4.95±2.01   | 5.25±1.77  | 0.651   | 4.61±1.69  | 5.76±1.59  | <0.001* |
| IIEF (sexual satisfaction) | 4.30±3.84 | 6.05±3.50 | 0.061 | 4.78±3.22 | 7.41±3.17 | <0.001* |
| IIEF (overall satisfaction) | 3.85±2.08 | 5.35±1.13 | 0.014* | 4.04±1.76 | 5.88±1.92 | <0.001* |
| IIEF (total)   | 28.20±18.01 | 37.75±17.31 | 0.049* | 29.73±14.89 | 43.86±14.74 | <0.001* |
| AMS (psychologic) | 10.19±7.09 | 10.48±5.96 | 0.902 | 7.20±4.78 | 9.57±5.16 | <0.001* |
| AMS (somatovegetative) | 18.92±16.53 | 25.47±18.06 | 0.028* | 14.10±6.20 | 21.28±14.60 | <0.001* |
| AMS (sexual)    | 14.50±16.94 | 15.09±16.35 | 0.463 | 11.60±6.50 | 12.40±5.27 | 0.233 |
| AMS (total)     | 37.23±20.21 | 47.48±24.34 | 0.007* | 32.89±15.01 | 43.67±21.43 | <0.001* |

Group 1: TDS patients with metabolic syndrome, Group 2: TDS patients without metabolic syndrome, IIEF: International Index of Erectile Function, AMS: The Aging Males’ Symptoms scale, *: statistical significance, p<0.05 in paired t-test between before and after TRT
DISCUSSION

TDS was officially jointly defined as late-onset hypogonadism (LOH) by the International Society of Andrology (ISA), the International Society for the Study of the Aging Male (ISSAM), and the European Association of Urology (EAU) in 2005 [7]. On the basis of that definition, the Korean Society for Aging Male Research (KOSAR) and the Korean Society for Sexual Medicine and Andrology suggested a Korean recommendation appropriate for domestic circumstances in 2006 [8]. Since then, in 2008, ISA, ISSAM, EAU, EAA (European Academy of Andrology), and ASA (American Society of Andrology) jointly announced the second amendment recommendation for the diagnosis, treatment, and monitoring of patients with testosterone deficiency. Although the definition of LOH remained the same as in the original recommendation, LOH and TDS are recommended to be used together [9].

Metabolic syndrome refers to the expression of risk factors of cardiovascular diseases such as obesity, hypertension, dyslipidemia, and glycometabolic abnormality, in addition to which the insulin resistance observed in type 2 diabetes is also characteristic [10,11]. Such metabolic defects occur at the same time and influence the overall body from the cardiovascular system to the nervous system to the endocrine system [11]. In particular, the relationship between metabolic syndrome and TDS has been the subject of consistent research. In 1977, Phillips reported that male patients with myocardial infarction exhibited insulin resistance and dyslipidemia along with a trend for reduced testosterone, and since then, there have been many reports studying the relationship between TDS and each risk factor of metabolic syndrome [12].

Among the risk factors for metabolic syndrome, insulin resistance is an important characteristic of type 2 diabetes mellitus, and the hyperinsulinemia caused by it is an important characteristic of type 2 diabetes [10,11]. In particular, the relationship from the cardiovascular system to the nervous system to the endocrine system [11]. In 2006 [8]. Since then, in 2008, ISA, ISSAM, EAU, EAA (European Academy of Andrology), and ASA (American Society of Andrology) jointly announced the second amendment recommendation for the diagnosis, treatment, and monitoring of patients with testosterone deficiency. Although the definition of LOH remained the same as in the original recommendation, LOH and TDS are recommended to be used together [9].

Metabolic syndrome refers to the expression of risk factors of cardiovascular diseases such as obesity, hypertension, dyslipidemia, and glycometabolic abnormality, in addition to which the insulin resistance observed in type 2 diabetes is also characteristic [10,11]. Such metabolic defects occur at the same time and influence the overall body from the cardiovascular system to the nervous system to the endocrine system [11]. In particular, the relationship between metabolic syndrome and TDS has been the subject of consistent research. In 1977, Phillips reported that male patients with myocardial infarction exhibited insulin resistance and dyslipidemia along with a trend for reduced testosterone, and since then, there have been many reports studying the relationship between TDS and each risk factor of metabolic syndrome [12].

Among the risk factors for metabolic syndrome, insulin resistance is an important characteristic of type 2 diabetes mellitus, and the hyperinsulinemia caused by it is an important characteristic of type 2 diabetes [10,11]. In particular, the relationship between metabolic syndrome and TDS has been the subject of consistent research. In 1977, Phillips reported that male patients with myocardial infarction exhibited insulin resistance and dyslipidemia along with a trend for reduced testosterone, and since then, there have been many reports studying the relationship between TDS and each risk factor of metabolic syndrome [12].
for their metabolic syndrome. Thus, it is necessary to categorize the patients according to the existence of treatment for metabolic syndrome during the TRT period and to compare the differences. Despite these limitations, however, it is significant that we were able to compare TRT treatment effectiveness in TDS patients according to the presence of metabolic syndrome.

CONCLUSIONS

When TRT is performed on patients with TDS, those also with metabolic syndrome showed improvements in fewer of the serum variables and survey results than did those without metabolic syndrome. Thus, the correction of metabolic syndrome, such as diabetes, obesity, and hypertension, should be considered during TRT.

Conflicts of Interest

The authors have nothing to disclose.

REFERENCES

1. 2005 life table of each city, district and cause of death in korea. The Department of Statistics. 2007;24.
2. Reaven GM. Banting Lecture 1988. 2ole of insulin resistance in human disease. Diabetes 1988;37:1595-607.
3. Albert KG, Zimmet PZ. Definition, diagnosis and classification of diabetes and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
6. Lee SY, Kim SC. Correlation of the serum testosterone level with insulin resistance and metabolic syndrome in patients of erectile dysfunction and benign prostatic hyperplasia. Korean J Urol 2008;49:556-61.
7. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 2006;27:135-7.
8. Kim MJ, Rhee Y, Seo JT, Yang DY, Moon DG, Park NC, et al. 2006 KOSAR recommendations for investigation, treatment and monitoring of LOH in males. Korean J Androl 2008;26:8-10.
9. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009;21:1-8.
10. Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ. Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Am J Epidemiol 1998;148:869-78.
11. Carantonio M, Zuliani G, Volpato S, Palmieri E, Mezzetti A, Vergnani L, et al. Relationships between fasting plasma insulin, anthropometrics, and metabolic parameters in a very old healthy population. Associazione Medica Sabin. Metabolism 1998;47:535-40.
12. Phillips GB. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci USA 1977;74:1729-33.
13. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992;35:173-7.
14. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234-8.
15. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992;117:807-11.
16. Andersson B, Mårin P, Lissner L, Vermeulen A, Björntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994;17:405-11.
17. Dhindsa S, Prabhakar S, Sethi M, Bandypadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotrophic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-8.
18. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-7.
19. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;71:929-31.
20. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991;40:101-4.
21. Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 1993;17:643-9.
22. Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism 1996;39:897-901.
23. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest 1999;22:110-6.
24. Rebuffé-Scrive M, Mårin P, Björntorp P. Effect of testosterone on cholesterol and apolipoprotein in healthy men. Metabolism 1990;39:897-901.
25. Hromadová M, Háčik T, Malatinský E, Riecanský I. Alterations of lipid metabolism in men with hypogonadotrophic hypogonadism. Horm Metab Res 1991;23:392-4.
26. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997;82:692-5.
27. Haffner SM, Mykkänen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993;77:1610-5.
28. Znuda JM, Caudley JA, Krica S, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 1997;146:609-17.
29. Whitset EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick
DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001;111:261-9.
30. Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001;86:1026-33.